Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Haas

Showing results (621-630 of 645) with videos related to

Pageof 65
Sort By:
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
ACS Central Science|February 27, 2023
Open-Source Chromatographic Data Analysis for Reaction Optimization and ScreeningChristian P Haas, Maximilian Lübbesmeyer, Edward H Jin, et al.
Cephalalgia : an International Journal of Headache|May 24, 2008
CACNA1A mutation linking hemiplegic migraine and alternating hemiplegia of childhoodB de Vries, A H Stam, F Beker, et al.
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
Klinische Padiatrie|October 26, 2013
Genotype-phenotype and genotype-origin correlations in children with mediterranean fever in Germany - an AID-net studyM Jeske, P Lohse, T Kallinich, et al.
JAMA Network Open|May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical TrialArun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Pediatric Rheumatology Online Journal|April 7, 2018
IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry)M Bielak, E Husmann, N Weyandt, et al.
The Journal of Urology|July 9, 2026
Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: ErratumNeal D Shore, Martin Gleave, Ugo De Giorgi, et al.
The Journal of Urology|July 9, 2026
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: ErratumNeal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
Pageof 65

Showing results (621-630 of 645) with videos related to

Sort By:
Pageof 65
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
ACS Central Science|February 27, 2023
Open-Source Chromatographic Data Analysis for Reaction Optimization and ScreeningChristian P Haas, Maximilian Lübbesmeyer, Edward H Jin, et al.
Cephalalgia : an International Journal of Headache|May 24, 2008
CACNA1A mutation linking hemiplegic migraine and alternating hemiplegia of childhoodB de Vries, A H Stam, F Beker, et al.
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
Klinische Padiatrie|October 26, 2013
Genotype-phenotype and genotype-origin correlations in children with mediterranean fever in Germany - an AID-net studyM Jeske, P Lohse, T Kallinich, et al.
JAMA Network Open|May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical TrialArun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Pediatric Rheumatology Online Journal|April 7, 2018
IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry)M Bielak, E Husmann, N Weyandt, et al.
The Journal of Urology|July 9, 2026
Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: ErratumNeal D Shore, Martin Gleave, Ugo De Giorgi, et al.
The Journal of Urology|July 9, 2026
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: ErratumNeal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
Pageof 65